高选择性 RET 抑制剂 selpercatinib 在治疗 RET 改变的甲状腺癌 (TC) 患者中显示出高效和良好的毒性特征。勃起功能障碍（ED）是晚期癌症患者中常见的不良事件。本研究旨在评估接受 selpercatinib 治疗的 TC 患者中 ED 的发生率。在一项多中心回顾性队列研究中，我们调查了 25 名接受 selpercatinib 治疗的晚期 TC 男性患者中 ED 的患病率。还检查了 ED 的管理。18/25 (78.3%) 患者在开始 selpercatinib 治疗后出现 ED。然而，只有 2/18 (11.1%) 自发报告 ED，而 16/18 (88.9%) 仅在特定询问后报告 ED。 10 名患者开始接受磷酸二酯酶 5 抑制剂 (PDE-5i) 治疗，ED 显着改善。在这项研究中，我们观察到，在接受 selpercatinib 治疗 RET 改变的 TC 的男性中，ED 的报道并不罕见。我们认为，临床医生应该积极询问此类患者的 ED 情况，因为这种情况可能被低估，但可能适合治疗。

The highly selective RET inhibitor selpercatinib showed high efficacy and favorable toxicity profile in treating patients with RET-altered thyroid cancer (TC). Erectile dysfunction (ED) is a common adverse event observed in patients with advanced cancers. This study aims to evaluate the occurrence of ED in TC patients treated with selpercatinib.In a multi-center retrospective cohort study, we investigated the prevalence of ED in 25 male patients treated with selpercatinib for advanced TC. The management of ED was also examined.18/25 (78.3%) patients presented ED after starting selpercatinib treatment. However, only 2/18 (11.1%) spontaneously reported ED, while 16/18 (88.9%) reported ED only after specific questioning. Ten patients started treatment with phosphodiesterase-5 inhibitors (PDE-5i) with a significant improvement of ED.In this study, we observed that ED was not infrequently reported among men treated with selpercatinib for RET-altered TC. We believe that clinicians should actively inquire about ED in such patients at it may be underreported but may be amenable to treatment.